Business Wire

Picsart, Gen Z’s Preferred Digital Content Creation Platform, Takes LinkedIn Creators to Dracula’s Castle for “Why Your Marketing Sucks” Halloween Campaign

22.10.2025 18:23:00 CEST | Business Wire | Press Release

Share

Picsart, the world’s leading digital creation platform, has announced the release of its new Halloween campaign and ebook, Why Your Marketing Sucks: a highly visual, tongue-in-cheek guide to the scariest mistakes marketers make and how to avoid them.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251022722043/en/

Why Your Marketing Sucks Ebook by Picsart

The campaign, running from October 15 through October 31, combines horror-themed storytelling with practical marketing advice and expertise. Its centerpiece, the Why Your Marketing Sucks ebook, was co-created by Picsart and five top LinkedIn marketing influencers during an exclusive brand trip to Transylvania to visit Bran Castle — thought to be the home of Count Dracula himself.

Picsart’s COO and Co-Founder, Mikayel Vardanyan, said “Gen Z represents more than 25% of today’s workforce. Picsart has been supporting this demographic for 15 years — more than half of our users are loyal Gen Z consumers — and we’re continuing to provide a creative home for fun and work as they evolve into this next stage of life. This campaign is designed to provide value in a fun and educational way for the new generation for marketers.”

A Creative First for B2B Marketing

From October 8 to 11, 2025, Picsart hosted the five influencers as they traveled across Romania. The experience began at Picsart’s Bucharest office, where creators met the team, enjoyed themed treats, and discussed the trip and plans ahead of them. The group then traveled to the Transylvania region for two days, first to Brasov for marketing meetings, where all influencers contributions were made to the ebook, and then to Bran for a private dinner and exclusive after-hours tour of Bran Castle (Dracula’s Castle): an atmospheric setting that inspired the campaign’s vampire-themed tone and gothic design.

While influencer trips are common for Instagram and TikTok creators, few brands have hosted a trip specifically for LinkedIn influencers, despite the platform being preferred by 8 out of 10 B2B marketers, as Tagembed highlights in their Top LinkedIn Statistics to Drive Engagement & Growth In 2025 report. Picsart developed the campaign to prioritize authentic co-creation, as opposed to traditional promotion through content on an influencer’s account. Picsart invited a select group of LinkedIn creators to collaborate in real time, building something that other marketers can access and use: a full-length ebook that entertains and educates.

“This type of content is so important to put out there because even if your marketing doesn’t suck, it’s very easy to get stuck in comfy ways that you stagnate. Challenging what you do can make you better in more ways than one,” said Rebecca Shipton, organic social media expert and one of the ebook’s co-authors.

Allanah Micallef, personal branding expert and co-author of the ebook, said “We know marketing moves fast - trends, advice, and updates drop daily. It’s easy to feel behind and to not know what’s worth following. That’s why this ebook matters. It’s not just a list of tips. It’s a collection of honest, practical truths you don’t usually see online.”

About Why Your Marketing Sucks: A Spooky Survival Guide for Modern Marketers

Released on October 15, Why Your Marketing Sucks is a Halloween-inspired marketing manual that highlights common marketing pitfalls and how to address them, while embodying Picsart’s signature visual creativity.

Each chapter explores the “scariest marketing mistake” for each niche, and how to fix it, covered by some of LinkedIn’s most recognizable creators:

  • Rebecca Shipton — Social Media: How to Revive an Audience
  • Sophie Miller — Content: How to Lure Them to Your Lair
  • Ashleen Narula — Community Building: How to Cultivate Your Coven
  • Eleshea Williams — Nonprofit Marketing: Raising Spirits and Funds
  • Allanah Micallef — Personal Branding: How to BRANd Yourself

Additional sections cover AI in marketing, campaign execution, and influencer strategy, created in partnership with Picsart’s internal team. Visually, the ebook embraces a gothic aesthetic, alongside typography provided by Monotype, making it a teaching tool and a free, informative piece for marketers.

The Why Your Marketing Sucks campaign has launched across Picsart’s LinkedIn, Instagram, email, a landing page, and the creators’ own social media channels. The ebook is free to download at https://picsart.com/why-your-marketing-sucks/. The campaign runs through October 31, culminating on Halloween itself.

About Picsart

Picsart is a recognized AI-powered platform for creative independence in a global economy increasingly driven and impacted by content. For over 15 years, Picsart has grown with and enabled the next generation of storytellers — Gen Z digital natives — to design, brand, and build at scale without limitations or barriers. With approximately 130+ million monthly active users and over 2 billion downloads, Picsart is well on its way to becoming the creative engine behind the $750 billion market of small businesses, entrepreneurs and brands, offering a range of innovative and intuitive tools and solutions that revolutionizes the creative, marketing and advertising processes. As creativity becomes central to identity, influence, entrepreneurship and profitability, Picsart is the platform for scalable, self-directed storytelling in a content-first economy

View source version on businesswire.com: https://www.businesswire.com/news/home/20251022722043/en/

Contacts

Media Contact:
Katie Russo, ThroughCo Communications
krusso@throughco.com
501-282-5069

(c) 2024 Business Wire, Inc., All rights reserved.

Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

BeOne Presents Compelling Data in Hard-to-Treat Liver and Lung Cancers at ESMO 202624.10.2026 10:15:00 CEST | Press Release

BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new data from multiple differentiated investigational medicines across its priority solid tumor disease areas at the European Society for Medical Oncology (ESMO) Congress 2026 (October 23–27, Madrid). The presentations span gastrointestinal, lung, and breast cancers, and reflect the growing momentum of BeOne’s solid tumor franchise. Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “At ESMO, we are showing how our strategy of matching the right modality to disease biology is translating into meaningful clinical progress. Our GPC3 x 4-1BB bispecific antibody continues to be well tolerated and demonstrates durable activity with longer follow up in patients with heavily pre-treated hepatocellular carcinoma, while the first clinical data from our brain-penetrant PRMT5 inhibitor and CEA-targeting ADC expand our innovation in non-small cell lung cancer. Alongsi

Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 19:42:00 CEST | Press Release

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Society of Nephrology (ASN) Kidney Week 2026 in Denver, Colorado, and advancement of the povetacicept clinical research program in IgAN. Vertex will also host an investor event during ASN on October 23 at 6:15-7 p.m. MDT (8:15-9 p.m. EDT). Further details are below. Data being presented include a pre-specified Week 36 interim analysis of the ongoing Phase 3 RAINIER trial of povetacicept, an engineered fusion protein and dual inhibitor of the BAFF (B cell activating factor) and APRIL (a proliferation inducing ligand) cytokines, in immunoglobulin A nephropathy (IgAN). RAINIER met its primary endpoint, with povetacicept achieving a 52.0% reduction from baseline in proteinuria at Week 36 and a statistically significant and clinically meaningful 49.8% reduction versus placebo (

Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 16:19:00 CEST | Press Release

Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com

BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 16:15:00 CEST | Press Release

BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “Following the U.S. approval in August, these longer-term data provide further evidence supporting TEVIMBRA plus ZIIHERA and chemotherapy as the new standard of care in all first-line HER2-positive advanced gastroesophageal adenocarcinoma patients, regardless of PD-L1 sta

inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 15:00:00 CEST | Press Release

inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a leading Central Asian economy, this gives the companies a clear basis to assess autonomous ride-hailing in practice. The three companies will evaluate the technical, operational, regulatory and

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye